Cost-effectiveness analysis: A reader's guide;L'analyse coût-efficacité: Un guide de lecture

Revue des Maladies Respiratoires

Volumn 20, Issue 1 I, 2003, Pages 116-125

  Vergnenegre A ^a  

^a Hopital du Cluzeau   (France)

Author keywords

Cost Effectiveness; Evidence Based Medicine; Lung Cancer; Treatment

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CAPTOPRIL; CISPLATIN; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; HYDROCHLOROTHIAZIDE; NAVELBINE; PACLITAXEL; THIAZIDE DIURETIC AGENT; VINCRISTINE; VINDESINE; ZIDOVUDINE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MAMMOGRAPHY; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; DATA INTERPRETATION, STATISTICAL; EVIDENCE-BASED MEDICINE; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; VINBLASTINE; VINDESINE;

EID: 0037322151     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Detsky AS, Naglie IG: A clinician's guide to cost-effectiveness analysis. Ann Intern Med 1990; 113: 147-54.
2. Meltzer MI: Introduction to health economics for physicians. Lancet 2001; 358: 993-8.
3. Less M, Aristides M, Maniakadis N, McKendrick J, Botwood N, Stephenson D: Economic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of non-small cell lung cancer. Pharmacoeconomics 2002; 20: 325-37.
4. Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos C, Samantas C: Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small cell lung cancer: a phase III randomized study. J Clin Oncol 2002; 20: 3578-85.
5. Chen YM, Perng RP, Lee YC, Shih JF, Lee CS, Tsai CM, Whang-Peng J: Paclitaxel plus carboplatin compared with paclitaxel plus gemcitabine shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable nonsmall cell lung cancer previously untreated. Ann Oncol 2002; 13: 108-15.
6. Ramsey SD, Moinpour CM, Lovato LC, Crowley JJ, Grevstad P, Presant CA, Rivkin SE, Kelly K, Gandara DR: Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J Natl Cancer Inst 2002; 94: 291-7.
7. Annemans L, Giaccone G, Vergnenegre A: The cost-effectiveness of paclitaxel (Taxol) + cisplatin is similar to that to teniposide + cisplatin in advanced non-small cell lung cancer: a multicountry analysis. Anticancer Drugs 1999; 10: 605-15.
8. Smith T, Hillner B, Neighbors D, McSorley P, Le Chevalier T: Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small cell lung cancer. J Clin Oncol 1995; 13: 2166-73.
9. ANAES. Analyse de la littérature et graduation des recommandations. Paris: Agence Nationale d'Accréditation et d'Evaluation en Santé, 2000: 64 p.
10. Drummond MF, Jefferson TO: Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. Bmj 1996; 313: 275-83.
11. Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Gold MR: Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine. Pharmacoeconomics 1997; 11: 159-68.
12. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB: Recommendations of the Panel on Cost-effectiveness in Health and Medicine. Jama 1996; 276: 1253-8.
13. Collège des Economistes de la Santé. Recommandations de bonnes pratiques des méthodes d'évaluation économique des stratégies thérapeutiques. La Lettre du Collège 1997: 1-16.
14. Drummond MF, Richardson WS, O'Brien BJ, Levine M, Heyland D: Users'guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. A. Are the results of the study valid? Jama 1997; 277: 1552-7.
15. Drummond MF, Stoddart GL, Torrance GW: Methods for the economic evaluation of health care programmes. Oxford, New-York, Toronto. Oxford University Press, 1987: 182 p.
16. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW: Méthodes d'évaluation économique des programmes de santé. Paris. Economica, 1997: 331 p.
17. Eccles M, Mason J, Freemantle N: Developing valid cost effectiveness guidelines: a methodological report from the north of England evidence based guideline development project. Qual Health Care 2000; 9: 127-32.
18. Fervers B, Spath HM, Philip T, Carrere MO: Intégration des critères économiques dans les recommandations pour la pratique clinique en cancérologie. Bull Cancer 1998; 85: 272-80.
19. Glennie JL, Torrance GW, Baladi JF, Berka C, Hubbard E, Menon D, Otten N, Rivière M: The revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals. Pharmacoeconomics 1999; 15: 459-68.
20. Murray CJ, Evans DB, Acharya A, Baltussen RM: Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ 2000; 9: 235-51.
21. Thompson SG, Barber JA: How should cost data in pragmatic randomised trials be analysed? Bmj 2000; 320: 1197-200.
22. Torrance GW, Blaker D, Detsky A, Kennedy W, Schubert F, Menon D, Tugwell P, Konchak R, Hubbard E, Firestone T: Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics. Pharmacoeconomics 1996; 9: 535-59.
23. Teboul F, Moatti J, Colin C: L'analyse économique des stratégies médicales: du conflit à la complémentarité avec la clinique. J Econ Med 1991; 9: 85-96.
24. Udvarhelyi IS, Colditz GA, Rai A, Epstein AM: Cost-effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly? Ann Intern Med 1992; 116: 238-44.
25. Drummond MF, Davies L: Economic analysis alongside clinical trials. Revisiting the methodological issues. Int J Technol Assess Health Care 1991; 7: 561-73.
26. Nuijten MJ, Brorens MJ, Hekster YA, van der Kuy A, Lockefeer JH, de Smet PA, Bonsel G, Pronk MH: Reporting format for economic evaluation. Part I: Application to the Dutch healthcare system. Pharmacoeconomics 1998; 14: 159-63.
27. Siegel JE, Weinstein MC, Russell LB, Gold MR: Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. Jama 1996; 276: 1339-41.
28. Torgerson D, Spencer A: Marginal costs and benefits. BMJ 1996; 312: 35-6.
29. Laupacis A, Feeny D, Desky A, Tugwell P: How attractive does a new technology have to be warrant adaptation and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146: 473-81.
30. Nuijten MJ, Pronk MH, Brorens MJ, Hekster YA, Lockefeer JH, de Smet PA, Bonsel G, van der Kuy A: Reporting format for economic evaluation. Part II: Focus on modelling studies. Pharmacoeconomics 1998; 14: 259-68.
31. O'Brien B, Heyland D, Richardson W, Levine M, Drummond M: Users'guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. B. What are the results and will they help me in caring for my patients? Jama 1997; 277: 1802-6.
32. Balas EA, Kretschmer RA, Gnann W, West DA, Borens A, Centor RM, Nerlich M, Gupta M, West TD, Soderstrom NS: Interpreting cost analyses of clinical interventions. Jama 1998; 279: 54-7.
33. Briggs A, Gray A: Using cost effectiveness information. Bmj 2000; 320: 246.
34. Evans W, Will B, Berthelot J: Cost-effectiveness of lung cancer treatment in HHHensen: Textbook of lung cancer. Londres. M Dunitz ed. 2000: 349-62.
35. Perrier A: Démythifier l'analyse décisionnelle. Rev Mal Respir 2002; 19: 545-8.
36. Bernard A, Binquet C, Lejeune C, Hagry O, Quantin C, Faivre J, Favre JP: Gestion diagnostique d'un nodule isolé de plus de 2 cm de diamètre. Rev Mal Respir 2002; 19: 569-76.